MX2017008078A - Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas. - Google Patents

Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.

Info

Publication number
MX2017008078A
MX2017008078A MX2017008078A MX2017008078A MX2017008078A MX 2017008078 A MX2017008078 A MX 2017008078A MX 2017008078 A MX2017008078 A MX 2017008078A MX 2017008078 A MX2017008078 A MX 2017008078A MX 2017008078 A MX2017008078 A MX 2017008078A
Authority
MX
Mexico
Prior art keywords
isopropoxypyridin
dihydropyridin
indazol
oxoethyl
triazol
Prior art date
Application number
MX2017008078A
Other languages
English (en)
Inventor
Dan Zhang
Chi LEE Yung-
Lee Alfred
Anthony Jr Marinaro William
Feng Tao
Bahl Deepak
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2017008078A publication Critical patent/MX2017008078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención incluye una composición granular que comprende el ingrediente activo (S)-N-(3-(6-isopropoxipiridin-3-il)-1H-indazol- 5-il)-1-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidr opiridin-1(2H)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamid a, en donde la cantidad total del ingrediente activo comprende, en % en peso, aproximadamente 60-90 % de la Forma 1 de HCI de (S)-N-(3-(6-isopropoxipiridin-3-il)-1H-indazol-5-il)-1-(2-(4-(4-( 1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il) -2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida, aproximadamente 10-30 % de HCI de (S)-N-(3-(6-isopropoxipiridin-3-il)-1H-indazol-5 -il)-1-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-iI)fenil)-3,6-dihidro piridin-1(2H)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida amorfo, y aproximadamente 0-5 % de la base libre amorfa de (S)-N-(3-(6-isopropoxipiridin-3-il)-1H-indazol-5-il)-1-(2-(4-(4-( 1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il) -2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida.
MX2017008078A 2014-12-19 2015-12-14 Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas. MX2017008078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094515P 2014-12-19 2014-12-19
PCT/US2015/065434 WO2016100152A1 (en) 2014-12-19 2015-12-14 (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations

Publications (1)

Publication Number Publication Date
MX2017008078A true MX2017008078A (es) 2017-09-28

Family

ID=56127414

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008078A MX2017008078A (es) 2014-12-19 2015-12-14 Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.

Country Status (11)

Country Link
US (1) US10058544B2 (es)
EP (1) EP3233079B1 (es)
JP (1) JP6657222B2 (es)
KR (1) KR20170094795A (es)
CN (1) CN106999474A (es)
AU (1) AU2015362849B2 (es)
BR (1) BR112017012558A2 (es)
CA (1) CA2971088A1 (es)
MX (1) MX2017008078A (es)
RU (1) RU2712148C2 (es)
WO (1) WO2016100152A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3052096T1 (en) 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
WO2021252316A1 (en) * 2020-06-12 2021-12-16 Merck Sharp & Dohme Corp. Granular composition of an erk inhibitor and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
RU2359670C2 (ru) * 2004-03-25 2009-06-27 Астеллас Фарма Инк. Композиция солифенацина или его соли для использования в твердом препарате
EP2260031B1 (en) * 2008-02-21 2015-10-07 Merck Sharp & Dohme Corp. Compounds that are erk inhibitors
WO2009147189A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
EP2316031B1 (en) * 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
US20140309234A1 (en) * 2013-03-10 2014-10-16 Angion Biomedica Corp Small molecule anti-fibrotic compounds and uses thereof

Also Published As

Publication number Publication date
RU2712148C2 (ru) 2020-01-24
RU2017125511A3 (es) 2019-04-23
EP3233079B1 (en) 2021-09-22
EP3233079A4 (en) 2018-08-22
AU2015362849B2 (en) 2020-05-07
JP6657222B2 (ja) 2020-03-04
WO2016100152A1 (en) 2016-06-23
CN106999474A (zh) 2017-08-01
EP3233079A1 (en) 2017-10-25
JP2017537955A (ja) 2017-12-21
US20180000803A1 (en) 2018-01-04
KR20170094795A (ko) 2017-08-21
RU2017125511A (ru) 2019-01-21
BR112017012558A2 (pt) 2018-01-02
US10058544B2 (en) 2018-08-28
AU2015362849A1 (en) 2017-06-15
CA2971088A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
MX2023003068A (es) Oxadiazoles fungicidas.
NZ766284A (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
SA520411990B1 (ar) مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
MX2017009892A (es) Agente terapeutico contra el colangiocarcinoma.
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2020005818A (es) Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2022001656A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
MY194116A (en) Pharmaceutical compounds
PH12014501157A1 (en) Pharmaceutical formulations
PH12016500988A1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
EA201892235A1 (ru) Гранулированная композиция для перорального применения
CR20220112A (es) Composiciones que comprenden tigolaner para el control de parásitos
MX2018006329A (es) Agente terapeutico para cancer de mama.
MX2017008078A (es) Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
EP3248603A4 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX2016013561A (es) Activadores de herg policiclicos.
IL239928B (en) Preparations containing (s)-1-(4-(4-(4,3-dichlorophenyl(piperidino-(3-(2-(5-methyl4,3,1-oxodiazol-2-yl)-benzo[b]furan -4-yloxy-2-propanol for the treatment of depression